ArticleDiabetes, obesity & metabolism2021
Longevity of the novel ConvaTec infusion set with Lantern technology.
Article in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03819634 (Longevity of Multi-Slitted Catheter, the Convatec Inset II With Lantern Technology), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longevity of Multi-Slitted Catheter, the Convatec Inset II With Lantern Technology
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review.Journal of diabetes science and technology · 2023Pooled it
- Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.Journal of diabetes science and technology · 2023Trial
- Automated Insulin Delivery for Type 1 Diabetes: Present and Future.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Development of a Real-time Force-based Algorithm for Infusion Failure Detection.Journal of diabetes science and technology · 2024Article
- Insulin Delivery Hardware: Pumps and Pens.Diabetes technology & therapeutics · 2024Article
- Development of the Extended Infusion Set and Its Mechanism of Action.Journal of diabetes science and technology · 2024Article
- In Vivo Study of the Inflammatory Tissue Response Surrounding a Novel Extended-Wear Kink-Resistant Insulin Infusion Set Prototype Compared With a Commercial Control Over Two Weeks of Wear Time.Journal of diabetes science and technology · 2023Article
- Frequency and Detection of Insulin Infusion Site Failure in the Type 1 Diabetes Exchange Online Community.Diabetes technology & therapeutics · 2023Article
- Impact of Infusion Set Materials and Designs on the Subcutaneous Response in People With Diabetes: A Rapid Review of the Literature.Journal of diabetes science and technology · 2023Review
- Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear.Diabetes technology & therapeutics · 2023Article
- Closed-loop insulin delivery: update on the state of the field and emerging technologies.Expert review of medical devices · 2022Review
- Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.Diabetes technology & therapeutics · 2022Article
- Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report.Journal of diabetes science and technology · 2022Article
- Current Status and Emerging Options for Automated Insulin Delivery Systems.Diabetes technology & therapeutics · 2022Review
- Insulin induces a progressive increase in the resistance of subcutaneous tissue to fluid flow: Implications for insulin pump therapy.Diabetes, obesity & metabolism · 2022Article
- Advances in Insulin Pump Infusion Sets Symposium Report.Journal of diabetes science and technology · 2021Article
- Barriers to Uptake of Insulin Technologies and Novel Solutions.Medical devices (Auckland, N.Z.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Current insulin infusion sets are approved for only 2-3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty-five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets (P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.